NOVO — Marts 2026
-
Novo Nordisk's financial health remains robust despite recent market challenges. The company reported a revenue of $47,399.42 million, with a three-year revenue growth rate of 21.3%. The company's profitability metrics are impressive, with an operating margin of 41.31% and a net margin of 33.14%. These figures indicate a strong ability to convert sales into profits. https://www.gurufocus.com/news/8666145/novo-nordisk-nvo-faces-tough-month-amid-competitive-pressures
-
Mens meget af opmærksomheden har fokuseret på Novo Nordisks CagriSema og hvordan det klarede sig i forhold til tirzepatid, opstod der samtidig en anden udvikling, der peger i en anden retning. Ikke mod at erstatte det, der eksisterer i dag, men mod at udvide det, der kan være muligt i morgen.
I videoen gennemgås de offentliggjorte fase 2-resultater for UBT251 - en næste generations trippelagonistbehandling, der udvikles af Novo og United Biotechnology. https://proinvestor.com/boards/131370
-
08:21
@Cupcake Det er nok mig der er lidt væk fra vinduet, men så vidt jeg kan regne ud giver det en dækning af de 73% af dem der er startet op på pillen, hvad med de restrende 27% som ikke er med statestikken
? -
Godmorgen
-
NOVO-PARTNER: HALVDELEN AF VÆGTTABSKUNDER I USA STARTER ONLINE
Hver anden person, der starter på vægttabsmedicin i USA, køber online. Det fortæller Zach Reitano, der er chef i telesundhedsselskabet Ro, i et interview med Børsen.
-
FINANS.DK...
ANALYTIKERE: NOVO ER NØDT TIL AT LAVE STORE OPKØB
Novo Nordisk er nødt til at gennemføre store opkøb, hvis den danske medicinalkoncern skal kunne følge med den voksende konkurrence, lyder vurderingen fra analytikerne.
-
Novos anbefaling sænkes til "neutral" hos Goldman Sachs https://proinvestor.com/investornyt/1416271/novos-anbefaling-saenkes-til-neutral-hos-goldman-sachs
-
Godmorgen
-
Why I'm Not Worried About Novo Nordisk Stock https://www.fool.com/investing/2026/03/02/why-im-not-worried-about-novo-nordisk-stock/
-
C25: Karakterbogen: Skuffende guidance for 2026
efterlader et svagt kursindtryk https://proinvestor.com/boards/131391 -
GLP-1s support heart attack recovery in rodents by relaxing tight blood vessels https://www.fiercebiotech.com/research/glp-1s-support-heart-attack-recovery-rodents-relaxing-tight-blood-vessels
-
Den her lyder loven. Sematuglid i slidgigt https://www.sciencealert.com/semaglutide-may-reverse-damage-caused-by-osteoarthritis-study-suggests
-
-
DNB Carnegie lowers its price target on $NVO to DKK 420 (from DKK 430) and reiterates its Buy rating.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind